¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"growth arrest line"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • midaxillary line
    Áß°£°Üµå¶û¼±, ¾×¿ÍÁß°£¼±
  • midclavicular line
    ºøÀåÁß°£¼±, ¼â°ñÁß°£¼±
  • milk line
    Á¥¼±, À¯¼±
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • maternal line
    ¸ð°è
  • mesiolingual line angle
    ¾ÈÂÊÇôÂʼ±°¢
  • mesio-occlusal line angle
    ¾ÈÂʱ³Çո鼱°¢, ¾ÈÂʸ¹°¸²¸é¼±°¢
  • neonatal line
    ½Å»ý¾Æ¼±, ù¼ºÀå¼±
  • nuchal line
    ¸ñ´ú¹Ì¼±
  • nasolabial line
    ÄÚÀÔ¼ú¼±
  • oblique line
    ºø±Ý, »ç¼±
  • orbitomeatal line
    ´«È®±Ó±¸¸Û¼±, ¾È¿Í¿ÜÀ̵µ¼±
  • plane-line articulator
    Æò¸é¼±±³ÇÕ±â
  • pure line selection
    ¼ø°èµµÅÂ
  • pectinate line
    ºø»ì¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • double line hemorrhage
    µÎÁÙÃâÇ÷
  • dynamic skin line
    µ¿ÀûÇǺμ±
  • growth defect
    ¼ºÀå°áÇÔ
  • growth delay
    ¼ºÀåÁö¿¬
  • growth-onset diabetes
    Ãʱâ´ç´¢º´
  • embryonic line
    ¹è¾Æ¼±
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • epiphyseal line
    »À³¡¼±, °ñ´Ü¼±
  • established cell line
    È®¸³¼¼Æ÷ÁÖ
  • excessive growth
    °úµµ¼ºÀå
  • exponential growth
    Áö¼öÁõ½Ä
  • exponential growth rate
    ´ë¼öÁõ½Ä·ü, Áö¼öÁõ½Ä·ü
  • fetal growth retardation
    žƼºÀåÁö¿¬
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷¼ºÀåÀÎÀÚ
  • fixation line
    Áֽü±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • highest nuchal line
    ÃÖ»óÇ×¼±(õÌß¾ú£àÊ).
  • highest nuchal line
    ¸ÇÀ§¸ñ´ú¹Ì¼±
  • highest nuchal line
    ÃÖ»ó Ç× ¼±(õÌß¾ú£àÊ), ¸ÇÀ§ ¸ñ´ú¹Ì ¼±.
  • iliopectineal line
    ÀåÄ¡°ñ¼±(íóö»ÍéàÍ).
  • iliopectineal line
    ÀåÄ¡°ñ¼±(ÀåÄ¡°ñ¼±).
  • inbred line
    ¼ø°è
  • indwelling line
    À¯Ä¡°ü
  • inferior gluteal line
    ¾Æ·¡º¼±â±Ù¼±
  • phosphorus line
    Àμ±(ìÝàÊ).
  • plane line articulator
    Æò¼±±³ÇÕ±â(øÁàÊÎáùêÐï).
  • posterior axillary line
    µÚ°Üµå¶û¼±
  • posterior axillary line =PAL
    µÚ°Üµå¶û¼±, Èľ׿ͼ±(ý­äýèÀàÊ).
  • posterior focal line
    ÈÄÃʼ±(ý­õ¥àÊ).
  • posterior gluteal line
    µÚº¼±â±Ù¼±
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • curve, growth
    Áõ½Ä°î¼±
  • curve, single-step growth
    ÀÏȸÁõ½Ä°î¼±
  • cycle, growth
    Áõ½ÄÁÖ±â
  • developmental disease =growth abnor mal ity
    ¹ß´ÞÀÌ»ó(¡­ì¶ßÈ).
  • economic growth
    °æÁ¦¼ºÀå.
  • endothelial cell growth factor
    ³»ÇǼ¼Æ÷ Áõ½ÄÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ(øúù«à÷íþì×í­)
  • epidermal growth factor
    Ç¥ÇǼºÀå ÀÎÀÚ(¡­à÷íþ ì×í­)
  • epidermal growth factor (EGF)
    ÇǺÎÁõ½ÄÀÎÀÚ
  • epidermal growth factor = EGF
    Ç¥ÇÇ ¼ºÀå ÀÎÀÚ
  • epidermoid growth factor
    Ç¥ÇÇ¾ç ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • essential growth factor
    ÇʼöÁõ½ÄÀÎÀÚ
  • excessive growth
    ¼ºÀå°úµµ
  • exponential growth
    Áö¼öÁõ½Ä.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Anocutaneous line
    Ç×¹®ÇǺμ±
    [¿¾ ¿ë¾î] Ç×¹®ÇǺμ±
  • Arcuate line
    Ȱ²Ã¼±
    [¿¾ ¿ë¾î] ±Ã»ó¼±
  • Cement line
    °áÇÕ¼±
    [¿¾ ¿ë¾î] °áÇÕ¼±
  • Z line
    ³¡»çÀ̸· [Z¼±]
    [¿¾ ¿ë¾î] Z¼±
  • Oblique line
    ºñ½ºµë¼±
    [¿¾ ¿ë¾î] »ç¼±
  • Oblique line
    ºø¼±
    [¿¾ ¿ë¾î] »ç¼±
  • M line
    Áß°£»çÀ̸· [M¼±]
    [¿¾ ¿ë¾î] M¼±
  • Resorption line
    Èí¼ö¼±
    [¿¾ ¿ë¾î] Èí¼ö¼±
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡(úìá³÷ùë¦ÕÎ) ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • step-growth polymer
    ´Ü°è¼ºÀå ÁßÇÕü(Ó«Í­à÷íþñìùêô÷)
  • synchronous growth
    µ¿±â¼ºÀå (ÔÒÑ¢à÷íþ)
  • tail growth
    ²¿¸®¼ºÀå (à÷íþ)
  • tailward growth
    ²¿¸®¹æÇâ ¼ºÀå (à÷íþ)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • unbalanced growth
    ºÒ±ÕÇü(ÝÕгû¬) ¼ºÀå (à÷íþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CPA Canadian Physiotherapy Association; Canadian Psychiatric Association; carboxypeptidase A; cardiopulm...
DHCA deep hypothermia and circulatory arrest
OHCA out-of-hospital cardiac arrest
OOH/CA out-of-hospital cardiac arrest
PAM pancreatic acinar mass; penicillin aluminum monostearate; peptidylglycine alpha-amidating monooxygen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CVL central venous line
CHO Chinese hamster ovary cell line
FSL Flinder sensitive line
FRL Flinders Resistant Line
FLN Fluorescence Line Narrowing
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alveolar ridge line
    Ä¡Á¶Á¤ ¼±
  • base line
    ±â¼±, ±âÀú¼±, ¹ÙÅÁ¼±
    ¹ÌÁ¤ÀÇ ¾çÀ̳ª °ªÀ» ÃøÁ¤ ¶Ç´Â ÆòÁ¤ÇÏ´Â µ¥ ¾²ÀÌ´Â ±âº»ÀÇ ¾ç ¶Ç´Â °ª.
  • base line shift
    ±âÁؼ± º¯À§
  • blood line
    Ç÷Á·, Ç÷Á·°è
  • Camper's line
    įÆÛ ¼±
    ºñÀÍÀÇ Çϴܰú ¿ÜÀ̵¹±âÀÇ »ó¿¬À» ¿¬°áÇÏ´Â ¼±.
  • cell line
    ¼¼Æ÷°è
  • cement line
    ½Ã¸àÆ® ¼±
    Ä¡°ü º¸Ã¶¹°À» Áö´ëÄ¡¿¡ Ä¡°ú¿ë ÇÕÂøÁ¦·Î ¿µ±¸ ÇÕÂø½ÃÄ×À» ¶§ ºÎÁ¤È®ÇÑ Á¢ÇÕÀ¸·Î ÇÕÂøÁ¦°¡ ³ëÃâµÇ´Â °Í.
  • cemental line
    ½Ã¸àÆ® ¼±
    °ñÀÇ È¾´Ü¸éÀÇ Çö¹Ì°æ °Ë»ç¿¡¼­ °üÂûµÇ´Â ¼±. °ñ´ÜÀ§ÀÇ °æ°è¸¦ ³ªÅ¸³½´Ù.
  • cervical line
    °æ¼±, Ä¡°æ¼±
    Ä¡±Ù°ú Ä¡°üÀÇ °æ°è¸¦ Ä¡°æ¼±À̶óÇÏ°í ¹ý¶û, ¹é¾ÇÁú °æ°è ºÎÀ§¸¦ ¶æÇϸç neck lineÀ̶ó°íµµ ÇÑ´Ù. ÀÌ ¼±Àº ¿µ±¸ ºÒº¯ÀÇ ¼±ÀÌ´Ù.
  • curve of dental cervical line
    Ä¡°æ ¼± ¸¸°î
  • double line hemorrhage
    µÎ ÁÙ ÃâÇ÷, Áß¼± ÃâÇ÷
  • facial line
    ¾È¸é ÁÖ¸§, ¾È¸é±¸
  • fulcrum line
    ÁöÁ¡ ¼±, Áö·¿ ¼±
  • high lip line
    »ó¼ø¼±
    À­ ÀÔ¼úÀÇ À§ÂÊ °æ°è.
  • incremental line
    ¹ßÀ°¼±
    Á¶Á÷ÀÇ °è¼ÓµÇ´Â Ä§ÂøÃþÀ» ³ªÅ¸³»´Â ¼±.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
growth hormone <endocrinology, hormone> Polypeptide (191 amino acids) produced by anterior pituitary that stimulates liver to produce somatomedins 1 & 2.
(13 Nov 1997)
growth hormone inhibiting hormone <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release.
(18 Nov 1997)
growth hormone-producing adenoma <tumour> An adenoma that produces the clinical picture of gigantism or acromegaly, although a third of the cells have no granules or are a mixture of acidophils and chromophobes; some tumours may secrete both growth hormone and prolactin; often an acidophil or eosinophil adenoma.
(05 Mar 2000)
growth hormone-regulating hormone <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin).
(18 Nov 1997)
growth hormone-releasing factor <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone.
Synonym: somatoliberin, growth hormone-releasing factor.
(20 Sep 2002)
growth hormone-releasing hormone <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone.
Synonym: somatoliberin, growth hormone-releasing factor.
(20 Sep 2002)
growth hormone stimulation test <investigation> A test which measures the level of human growth hormone in response to the administration of the amino acid arginine. This test measures the ability of the pituitary gland to secrete growth hormone. Normal values in children are: 48 ng/ml. Normal values in men are 10 ng/ml. Normal values in women are 15 ng/ml. This test is used to evaluate infants with growth retardation. It may also be part of an evaluation for a pituitary tumour. Failure of arginine to raise growth hormone levels may indicate hypopituitarism or dwarfism.
(27 Sep 1997)
growth hormone suppression test <investigation> A test to determine if growth hormone is suppressed by hyperglycaemia. Growth hormone blood levels are determined sequentially after ingestion of a glucose-rich meal. If growth hormone levels remain elevated (after the glucose is given) then acromegaly or gigantism is suspected.
(27 Sep 1997)
growth inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators).
(12 Dec 1998)
growth medium <cell culture> A synthetic medium which is filled with nutrients necessary to the growth of microorganisms or cells being cultured in the lab.
(09 Oct 1997)
growth milestones <paediatrics>
(1-3 years) In ascending order: masters walking, recognises gender differences, uses up to 8 words and understands simple commands, able to run, pivot and walk backwards, uses spoon to feed self, can name pictures of common objects, can point to body parts, imitates speech of others, begins pedaling tricycle, learns to take turns in play with other children, able to feed self neatly with minimal spill, able to say first and last name, able to draw a line when shown, dresses self with minimal help, learns to share toys without parent direction
(12-18 years) In ascending order: boys exhibit secondary sexual characteristics (chest, facial, axillary and pubic hair growth voice changes, penile enlargement), movement into adult height/weight category, cognitive abilities move from simply concrete to abstract, peer acceptance and recognition is vital
(3-6 years) In ascending order: rides tricycle well, able to draw a circle, able to draw stick figures, hops on one foot, catches a bounced ball, understands size concepts, enjoys rhymes and word play, able to skip, increased independence in performing tasks without parental assistance, begins to ride bicycle, understands time concepts, begins to recognise written words, starts reading skills, starts school
(6-12 years) In ascending order: understands and is able to follow sequential directions, beginning skills for team sports, begins to lose baby teeth and erupt permanent teeth, reading skills develop further, peer recognition becomes important, girls begin to demonstrate secondary sexual characteristics (pubic hair, axillary hair, breast development), first menstrual period may occur
(birth-1 year) In ascending order: displays social smile, rolls over by self, able to sit alone without support, babbling, plays peek-a-boo, eruption of first tooth, pulls self to standing position, walks while holding on to furniture or other support, says mama or dada in proper situations, able to drink from cup, understands NO and will stop activity in response, walks without support
(27 Sep 1997)
growth-onset diabetes A chronic condition in which the pancreas makes little or no insulin because the beta cells have been destroyed. The body is then not able to use the glucose (blood sugar) for energy. IDDM usually comes on abruptly, although the damage to the beta cells may begin much earlier. The signs of IDDM are a great thirst, hunger, a need to urinate often, and loss of weight. To treat the disease, the person must inject insulin, follow a diet plan, exercise daily, and test blood glucose several times a day. IDDM usually occurs in children and adults who are under age 30. This type of diabetes used to be known as juvenile diabetes, juvenile-onset diabetes, and ketosis-prone diabetes.
(09 Oct 1997)
growth phase <microbiology> The characteristic periods in the growth of a bacterial culture, as indicated by the shape of a graph of viable cell number versus time.
(09 Oct 1997)
growth plate <physiology> The area between the epiphysis and the diaphysis within which bone growth occurs.
(12 Dec 1998)
growth quotient <biology> The fractional part or percentage of the entire food energy which is utilised for growth in the young animal.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • crow line
    ÀÏÁ÷¼±(beeline)
  • date line
    ³¯Â¥ º¯°æ¼±;³¯Â¥±âÀÔ¼±;(±â»çµî¿¡)¹ß½ÅÁö¿Í ³¯Â¥¸¦ ±âÀÔÇÑ´Ù
  • datum line
    ±âÁؼ±
  • destruct line
    (¹Ì»çÀÏÀÇ)ÀÚÆø¼±
  • dotted line
    Á¡¼±;(Áöµµ¿¡ Àû¾î ³ÖÀº)¿¹Á¤ ÄÚ½º;¹«Á¶°Ç µ¿ÀÇÇÏ´Ù
  • end line
    ³¡(ÇѰè,°æ°è)À» ³ªÅ¸³»´Â ¼±;(Å״Ͻº,³ó±¸,¹Ì½Ä Ã౸ µîÀÇ)¿£µå ¶óÀÎ
  • equinoctial circle (line)
    (õ)ÁÖ¾ß ÆòºÐ¼±
  • fall line
    ÆøÆ÷¼±;Æò¿ø°ú ÇØ¾È Æò¾ß¿ÍÀÇ ÇѰ輱;ÃÖ´ë °æ»ç¼±
  • fathom line
    Ãø¿¬¼±
  • fault line
    ´ÜÃþ¼±
  • feeder line
    Áö¼±
  • field line
    ÈûÀÇ ¼±
  • finish line
    °á½Â¼±
  • fire line
    ¹æÈ­¼±;¼Ò¹æ ½Ã»ó¼±
  • firing line
    »ç¼±;Æ÷¿­¼±;»ç¼±ºÎ´ë;Á¦Àϼ±;ÃÖ¼±ºÀ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á